ABSTRACT
BACKGROUND: The COVID-19 pandemic has brought significant mental health challenges, particularly for vulnerable populations, including non-binary gender individuals. The COMET international study aimed to investigate specific risk factors for clinical depression or distress during the pandemic, also in these special populations. METHODS: Chi-square tests were used for initial screening to select only those variables which would show an initial significance. Risk Ratios (RR) were calculated, and a Multiple Backward Stepwise Linear Regression Analysis (MBSLRA) was followed with those variables given significant results at screening and with the presence of distress or depression or the lack of both of them. RESULTS: The most important risk factors for depression were female (RR = 1.59-5.49) and non-binary gender (RR = 1.56-7.41), unemployment (RR = 1.41-6.57), not working during lockdowns (RR = 1.43-5.79), bad general health (RR = 2.74-9.98), chronic somatic disorder (RR = 1.22-5.57), history of mental disorders (depression RR = 2.31-9.47; suicide attempt RR = 2.33-9.75; psychosis RR = 2.14-10.08; Bipolar disorder RR = 2.75-12.86), smoking status (RR = 1.15-5.31) and substance use (RR = 1.77-8.01). The risk factors for distress or depression that survived MBSLRA were younger age, being widowed, living alone, bad general health, being a carer, chronic somatic disorder, not working during lockdowns, being single, self-reported history of depression, bipolar disorder, self-harm, suicide attempts and of other mental disorders, smoking, alcohol, and substance use. CONCLUSIONS: Targeted preventive interventions are crucial to safeguard the mental health of vulnerable groups, emphasizing the importance of diverse samples in future research. LIMITATIONS: Online data collection may have resulted in the underrepresentation of certain population groups.
Subject(s)
COVID-19 , Substance-Related Disorders , Humans , Female , Male , COVID-19/epidemiology , Mental Health , Pandemics , Population Groups , Vulnerable Populations , Communicable Disease Control , Substance-Related Disorders/epidemiology , Depression/epidemiologyABSTRACT
BACKGROUND: The prevalence of medical illnesses is high among patients with psychiatric disorders. The current study aimed to investigate multi-comorbidity in patients with psychiatric disorders in comparison to the general population. Secondary aims were to investigate factors associated with metabolic syndrome and treatment appropriateness of mental disorders. METHODS: The sample included 54,826 subjects (64.73% females; 34.15% males; 1.11% nonbinary gender) from 40 countries (COMET-G study). The analysis was based on the registration of previous history that could serve as a fair approximation for the lifetime prevalence of various medical conditions. RESULTS: About 24.5% reported a history of somatic and 26.14% of mental disorders. Mental disorders were by far the most prevalent group of medical conditions. Comorbidity of any somatic with any mental disorder was reported by 8.21%. One-third to almost two-thirds of somatic patients were also suffering from a mental disorder depending on the severity and multicomorbidity. Bipolar and psychotic patients and to a lesser extent depressives, manifested an earlier (15-20 years) manifestation of somatic multicomorbidity, severe disability, and probably earlier death. The overwhelming majority of patients with mental disorders were not receiving treatment or were being treated in a way that was not recommended. Antipsychotics and antidepressants were not related to the development of metabolic syndrome. CONCLUSIONS: The finding that one-third to almost two-thirds of somatic patients also suffered from a mental disorder strongly suggests that psychiatry is the field with the most trans-specialty and interdisciplinary value and application points to the importance of teaching psychiatry and mental health in medical schools and also to the need for more technocratically oriented training of psychiatric residents.
Subject(s)
Antipsychotic Agents , Mental Disorders , Metabolic Syndrome , Male , Female , Humans , Metabolic Syndrome/epidemiology , Metabolic Syndrome/drug therapy , Mental Disorders/epidemiology , Mental Disorders/drug therapy , Antipsychotic Agents/therapeutic use , Mental Health , ComorbidityABSTRACT
The early psychological impact of the COVID-19 pandemic and lockdown is greater in people with mental disorders. This study explored the differences in the psychological impact on people with an anxiety disorder by sex in Spain.
Subject(s)
COVID-19 , Humans , Female , Male , Pandemics , Sex Characteristics , Anxiety/epidemiology , SARS-CoV-2 , Communicable Disease Control , Anxiety Disorders/epidemiology , Anxiety Disorders/psychology , DepressionABSTRACT
Introducción. El impacto psicológico en las etapas iniciales de la pandemia por COVID-19 y el confinamiento fue mayor en personas con trastornos mentales. En este estudio se exploraron las diferencias en el impacto psicológico según el sexo en personas con trastorno de ansiedad en España. Metodología. Estudio transversal, descriptivo y comparativo de los datos aportados por los participantes en una encuesta online anónima realizada entre el 19 y el 26 de marzo de 2020. El cuestionario ad hoc incluyó datos sociodemográficos, clínicos y variables relacionadas con COVID-19,junto con preguntas sobre estrategias de afrontamiento y las versiones en español de la Escala de Escalas de Depresión Ansiedad Estrés (DASS-21) y la Escala de Impacto del Estresor(IES). Se utilizaron análisis descriptivos bivariados y modelos de regresión logística. Resultados. De los 21.207 participantes, se analizaron1617 (7,6%) personas con trastorno de ansiedad autoinformado [1347 (83,3%) mujeres; 270 (16,7%) varones]. El impacto psicológico fue mayor en las mujeres que en los hombres con diferencias estadísticamente significativas en cada subescala del DASS-21 y subescalas del IES. Después de ajustar por posibles variables de confusión, se observó que ser mujer se asoció con puntuaciones más altas en las subescalas de pensamientos intrusivos y evitativos. Conclusiones. Nuestro estudio sugiere que las mujeres con trastorno de ansiedad son un grupo vulnerable a un mayor impacto negativo en la salud mental y, especialmente, en los síntomas relacionados con el trastorno de estrés postraumático. (AU)
Background. The early psychological impact of the COVID-19 pandemic and lockdown is greater in peoplewith mental disorders. This study explored the differences in the psychological impact on people with an anxiety disorder by sex in Spain. Methods. Cross-sectional, descriptive, comparative study of the data provided by participants in an anonymous online survey between March 19 and 26, 2020. Thead hoc questionnaire included sociodemographic, clinical,and variable data related to COVID-19, along with questions about coping strategies, and the Spanish versions ofthe Depression, Anxiety, and Stress Scale (DASS-21) andImpact of Event Scale (IES). Descriptive bivariate analyses and logistic regression models were used. Results. Of the 21,207 participants, 1617 (7.6%) people with self-reported anxiety disorder were analyzed [1347(83.3%) females; 270 (16.7%) males]. The psychological impact was greater on women than men with statistically significant differences in each subscale of the DASS-21and subscales of the IES. After adjusting for potential confounding variables, it was observed that being awoman was associated with higher scores on the intrusiveand avoidant thoughts subscales. Conclusions. Our study suggests that women with ananxiety disorder are a group vulnerable to a greater negative impact on mental health and, especially, symptomsr elated to post-traumatic stress disorder. (AU)
Subject(s)
Humans , Male , Female , Psychosocial Impact , Pandemics , Coronavirus Infections/epidemiology , Anxiety Disorders/psychology , Sex Distribution , Spain , Cross-Sectional Studies , Epidemiology, Descriptive , PsychologyABSTRACT
INTRODUCTION: The current study aimed to investigate the rates of anxiety, clinical depression, and suicidality and their changes in health professionals during the COVID-19 outbreak. MATERIALS AND METHODS: The data came from the larger COMET-G study. The study sample includes 12,792 health professionals from 40 countries (62.40% women aged 39.76 ± 11.70; 36.81% men aged 35.91 ± 11.00 and 0.78% non-binary gender aged 35.15 ± 13.03). Distress and clinical depression were identified with the use of a previously developed cut-off and algorithm, respectively. STATISTICAL ANALYSIS: Descriptive statistics were calculated. Chi-square tests, multiple forward stepwise linear regression analyses, and Factorial Analysis of Variance (ANOVA) tested relations among variables. RESULTS: Clinical depression was detected in 13.16% with male doctors and 'non-binary genders' having the lowest rates (7.89 and 5.88% respectively) and 'non-binary gender' nurses and administrative staff had the highest (37.50%); distress was present in 15.19%. A significant percentage reported a deterioration in mental state, family dynamics, and everyday lifestyle. Persons with a history of mental disorders had higher rates of current depression (24.64% vs. 9.62%; p < 0.0001). Suicidal tendencies were at least doubled in terms of RASS scores. Approximately one-third of participants were accepting (at least to a moderate degree) a non-bizarre conspiracy. The highest Relative Risk (RR) to develop clinical depression was associated with a history of Bipolar disorder (RR = 4.23). CONCLUSIONS: The current study reported findings in health care professionals similar in magnitude and quality to those reported earlier in the general population although rates of clinical depression, suicidal tendencies, and adherence to conspiracy theories were much lower. However, the general model of factors interplay seems to be the same and this could be of practical utility since many of these factors are modifiable.
Subject(s)
COVID-19 , Humans , Female , Male , COVID-19/epidemiology , Mental Health , Suicidal Ideation , Depression/epidemiology , Anxiety/epidemiology , Anxiety/psychology , Health PersonnelABSTRACT
BACKGROUND: Subjective response (SR) to antipsychotic medication is relevant for quality of life, adherence and recovery. Here, we evaluate (1) the extent of variation in SR in patients using a single antipsychotic; (2) the association between subjective and symptomatic response; and (3) predictors of SR. METHODS: Open-label, single treatment condition with amisulpride in 339 patients with a first episode of a schizophrenia spectrum disorder, at most minimally treated before inclusion. Patients were evaluated at baseline, before start with amisulpride and after four weeks of treatment with the Subjective Wellbeing under Neuroleptic scale, the Positive and Negative Syndrome Scale, and the Calgary Depression Scale for Schizophrenia. RESULTS: (1) 26.8% of the patients had a substantial favorable SR, and 12.4% of the patients experienced a substantial dysphoric SR during treatment with amisulpride. (2) Modest positive associations were found between SR and 4 weeks change on symptom subscales (r = 0.268-0.390, p values < 0.001). (3) Baseline affective symptoms contributed to the prediction of subjective remission, demographic characteristics did not. Lower start dosage of amisulpride was associated with a more favorable SR (r = -0.215, p < 0.001). CONCLUSIONS: We conclude that variation in individual proneness for an unfavorable SR is substantial and only modestly associated with symptomatic response. We need earlier identification of those most at risk for unfavorable SR and research into interventions to improve SR to antipsychotic medication in those at risk.
Subject(s)
Amisulpride , Antipsychotic Agents , Schizophrenia , Humans , Amisulpride/adverse effects , Antipsychotic Agents/adverse effects , Quality of Life/psychology , Schizophrenia/drug therapy , Treatment OutcomeABSTRACT
INTRODUCTION: During the COVID-19 pandemic various degrees of lockdown were applied by countries around the world. It is considered that such measures have an adverse effect on mental health but the relationship of measure intensity with the mental health effect has not been thoroughly studied. Here we report data from the larger COMET-G study pertaining to this question. MATERIAL AND METHODS: During the COVID-19 pandemic, data were gathered with an online questionnaire from 55,589 participants from 40 countries (64.85% females aged 35.80 ± 13.61; 34.05% males aged 34.90±13.29 and 1.10% other aged 31.64±13.15). Anxiety was measured with the STAI, depression with the CES-D and suicidality with the RASS. Distress and probable depression were identified with the use of a previously developed cut-off and algorithm respectively. STATISTICAL ANALYSIS: It included the calculation of Relative Risk (RR), Factorial ANOVA and Multiple backwards stepwise linear regression analysis RESULTS: Approximately two-thirds were currently living under significant restrictions due to lockdown. For both males and females the risk to develop clinical depression correlated significantly with each and every level of increasing lockdown degree (RR 1.72 and 1.90 respectively). The combined lockdown and psychiatric history increased RR to 6.88 The overall relationship of lockdown with severity of depression, though significant was small. CONCLUSIONS: The current study is the first which reports an almost linear relationship between lockdown degree and effect in mental health. Our findings, support previous suggestions concerning the need for a proactive targeted intervention to protect mental health more specifically in vulnerable groups.
Subject(s)
COVID-19 , Suicide , Anxiety/epidemiology , Anxiety/psychology , Communicable Disease Control , Depression/epidemiology , Depression/psychology , Female , Humans , Male , PandemicsABSTRACT
Background: A previously published meta-analysis found that about one-third of the general population experienced some mental health problem during the early phase of the COVID-19 pandemic, potentially leading to a late mental health crisis. We aimed to describe the acute, short-term, and long-term effects of the COVID-19 pandemic on mental health. Methods: A one-year online survey (S) was conducted in Spain (April 2020 - March 2021). We recruited 18 180 subjects using a virtual respondent-driven snowball sampling method (S1 April 2020, n = 6108; S2 October-November 2020, n = 6418; S3 March 2021, n = 5654). Participants completed the Spanish Depression, Anxiety, and Stress Scale (DASS-21). Results: Overall, our results suggest a progressive increase in the prevalence of anxiety and stress throughout the pandemic waves and relative stability of depression. Women had a greater probability of having depression, anxiety, or stress than men in each survey (P < 0.001). The youngest group (aged 18-24) reported a higher probability (P < 0.05) of having depression, anxiety, or stress than the older groups in S1 and S2. Middle-aged people (25-59) had a greater probability of being a case in the DASS-21 scales than the oldest group (60+), except for depression in men (P = 0.179). In S3, the trend changed: the youngest group showed a decrease in depression and stress while the oldest group showed a dramatic increase (anxiety: men = 664.5%, women = 273.52%; stress: men = 786%, women = 431.37%). Conclusions: It is plausible to conclude that COVID-19 psychological fatigue exists, especially in middle-aged and older adults. Strategies to assist people who have fewer coping skills should be implemented in the near future.
Subject(s)
COVID-19 , Mental Fatigue , Adult , Aged , COVID-19/epidemiology , COVID-19/psychology , Cross-Sectional Studies , Depression/epidemiology , Female , Humans , Male , Mental Fatigue/epidemiology , Middle Aged , Pandemics , SARS-CoV-2 , Spain/epidemiology , Surveys and QuestionnairesABSTRACT
INTRODUCTION: Apathy is a negative symptom of schizophrenia and is associated with poor real world functioning. Therefore, it is important to have validated psychometric instruments to assess this symptom. This is the first study to validate the Spanish adaptation of the self-rated version of the Apathy Assessment Scale (AES-S) in patients with schizophrenia. MATERIALS AND METHODS: Naturalistic, cross-sectional, validation study in 104 patients with schizophrenia evaluated using the following scales: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS), and Apathy Evaluation Scale-self-rated version (AES-S). RESULTS: Reliability: Internal consistency (Cronbach's alpha) was 0.908. Convergent validity: The Pearson correlation coefficient between AES-S and CAINS-MAP total scores was -0.483 (p<0.001). For SNS, total and avolition subscale scores were -0.803 and -0.639 (p<0.001), respectively. With the MAP-SR, the correlation coefficient was -0.727 (p<0.001). Divergent validity: The Pearson correlation coefficient between AES-S and PSP total scores was 0.504 (p<0.001). Furthermore, with the CDSS, the correlation coefficient was -0.431 (p<0.001). Discriminant validity: The AES-S discriminated between different levels of illness severity according to CGI-S scores. Factor analysis: A three-component solution explained 57.32% of the variance. Pearson correlations between coefficients were 1-2=0.265, 1-3=0.464, and 2-3=0.060. CONCLUSION: The Spanish AES-S is a reliable and valid instrument for assessing apathy in Spanish patients with schizophrenia. It seems to be appropriate for use in everyday clinical practice as a means of monitoring apathy in these patients.
Subject(s)
Apathy , Schizophrenia , Cross-Sectional Studies , Humans , Psychiatric Status Rating Scales , Reproducibility of Results , Schizophrenia/diagnosisABSTRACT
INTRODUCTION: Negative symptoms can be grouped into five domains: apathy/avolition, anhedonia, asociality, alogia, and affective flattening. There are few validate self-rated measures that assess these five dimensions. Therefore, this study aimed to validate the Self-Evaluation of Negative Symptoms (SNS) in Spanish patients with schizophrenia. MATERIAL AND METHODS: Cross-sectional, validation study in 104 outpatients with schizophrenia evaluated using the Spanish version of the following scales: Clinical Assessment Interview for Negative Symptoms (CAINS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale for Schizophrenia (CGI-SCH), Personal and Social Performance (PSP), Motivation and Pleasure Scale - Self-Report (MAP-SR), 36-item Short-Form Health Survey (SF-36) and the Self-Evaluation of Negative Symptoms (SNS). RESULTS RELIABILITY: Internal consistency (Cronbach's alpha) was 0.915. Convergent validity: The Pearson correlation coefficient between MAP-SR and SNS Total scores was 0.660 (p<0.001). For PANSS-N, the correlation was 0.437 (p<0.005) and with the CAINS-Total was 0.478 (p<0.005). Divergent validity: The Pearson correlation coefficient between SNS and PSP was r=-0.372 (p≤0.001), and with SF-36 Physical and Mental Summary Component scores were r=-0.213 (p=0.066) and r=-0.144 (p=0.219), respectively. Discriminant validity: SNS Total scores were significantly statistically different according to the severity of the negative symptomatology rated by the CGI-SCH negative scale (p<0.001). CONCLUSION: The SNS is a reliable and valid instrument to self-rate the five domains of negative symptoms in patients with schizophrenia and seems to be appropriate for use in everyday clinical practice as a complementary measure to the evaluation performed by the clinician.
Subject(s)
Schizophrenia , Cross-Sectional Studies , Diagnostic Self Evaluation , Humans , Psychiatric Status Rating Scales , Psychometrics , Reproducibility of Results , Schizophrenia/diagnosisSubject(s)
COVID-19 , Suicidal Ideation , Humans , COVID-19/epidemiology , COVID-19/psychology , Pandemics , Risk Factors , Spain/epidemiologyABSTRACT
BACKGROUND: There are few studies that relate eating and nutritional habits to the severity of the disease and demographic profile in patients with schizophrenia. OBJECTIVE: To describe eating and nutritional habits and their relationship with the severity of the disease in patients with schizophrenia. METHOD: Cross-sectional descriptive study. SAMPLE: 31 patients with schizophrenia (ICD-10) under outpatient treatment. INCLUSION CRITERIA: age 18-65 years, clinically stable and, written informed consent. ASSESSMENT: Demographic, clinical characteristics (CGI-SCH, length of illness, BMI, abdominal perimeter), ad hoc questionnaire (eating, nutritional, and physical activity). RESULTS: Mean age 43.13(SDâ¯=â¯7.85) years, males 61.3%. Mean severity of illness was 3.94(SDâ¯=â¯1.06), mean duration of the illness 18.42(SDâ¯=â¯8.27) years. 74.2% used to eatweekly fat meat and 64.5% less than 3-4 servings of fish, 77.4% less than 3 servings of fruit per day, and 51.6% drink less than 1â¯L of water. 83.9% used to drink coffee daily, 2.81(SDâ¯=â¯2.02) cups per day. Patients showed lower levels of Vitamin A, D, E, K1, C, folic acid, and magnesium. 93.5% did not fulfill the WHO recommendations on physical activity. Only retinol (râ¯=â¯-0.602, Pâ¯=â¯.039) and vitamin K1 (râ¯=â¯-0.693, Pâ¯=â¯.012) in women were related to the severity of illness. CONCLUSIONS: Outpatients with schizophrenia do not follow WHO recommendations on healthy diets, neither physical activity. Both clinical severity of the illness and marital status and cohabitation were associated with poor eating habits and nutrients deficit. These data should be taken into account by the nursing staff when implementing specific care in routine clinical practice.
Subject(s)
Schizophrenia , Adolescent , Adult , Aged , Animals , Cross-Sectional Studies , Exercise , Feeding Behavior , Female , Habits , Humans , Male , Middle Aged , Young AdultABSTRACT
Antecedentes: Hay pocos estudios que relacionen los hábitos alimenticios y nutricionales con la gravedad de la enfermedad y el perfil demográfico en pacientes con esquizofrenia.Objetivo: Describir los hábitos alimenticios y nutricionales y su relación con la gravedad de la enfermedad en pacientes con esquizofrenia.Método: Estudio descriptivo transversal. Muestra: 31 pacientes con esquizofrenia (CIE-10) en tratamiento ambulatorio. Criterios de inclusión: edad 18-65 años, clínicamente estable y consentimiento informado por escrito. Evaluación: características demográficas, clínicas (ICG-G, años de evolución de la enfermedad, IMC, perímetro abdominal), cuestionario ad hoc (alimentación, hábito nutricional y actividad física).Resultados: Edad media 43,13 (DE = 7,85) años, varones 61,3%. La gravedad media de la enfermedad fue de 3,94 (DE = 1,06), con una media de 18,42 (DE = 8,27) años evolución de la enfermedad. El 74,2% comía carne grasa semanalmente y el 64,5% menos de 3-4 porciones de pescado, el 77,4% menos de 3 porciones de fruta por día y el 51,6% bebía menos de un litro de agua. El 83,9% tomaba café diariamente, 2,81 (DE = 2,02) cafés por día. Los pacientes presentaban niveles más bajos de vitamina A, D, E, K1, C, ácido fólico y magnesio. El 93,5% no cumplía con las recomendaciones de la OMS sobre actividad física. Solo el retinol (r = -0,602, p = 0,039) y la vitamina K1 (r = -0,693, p = 0,012) en las mujeres se relacionaron con la gravedad de la enfermedad.Conclusiones:Los pacientes con esquizofrenia a seguimiento ambulatorio no siguen las recomendaciones de la OMS sobre dietas saludables ni actividad física. Tanto la gravedad clínica de la enfermedad como el estado civil y la convivencia se asociaron con malos hábitos alimenticios y déficit de nutrientes. Estos datos deben ser tenidos en cuenta por el personal de enfermería a la hora de implementar cuidados específicos en la práctica clínica habitual. (AU)
Background: There are few studies that relate eating and nutritional habits to the severity of the disease and demographic profile in patients with schizophrenia.Objective: To describe eating and nutritional habits and their relationship with the severity of the disease in patients with schizophrenia.Method: Cross-sectional descriptive study. Sample: 31 patients with schizophrenia (ICD-10) under outpatient treatment. Inclusion criteria: age 18-65 years, clinically stable and, written informed consent. Assessment: Demographic, clinical characteristics (CGI-SCH, length of illness, BMI, abdominal perimeter), ad hoc questionnaire (eating, nutritional, and physical activity).Results : Mean age 43.13(SD=7.85) years, males 61.3%. Mean severity of illness was 3.94(SD=1.06), mean duration of the illness 18.42(SD=8.27) years. 74.2% used to eat weekly fat meat and 64.5% less than 3-4 servings of fish, 77.4% less than 3 servings of fruit per day, and 51.6% drink less than 1l of water. 83.9% used to drink coffee daily, 2.81(SD=2.02) cups per day. Patients showed lower levels of Vitamin A, D, E, K1, C, folic acid, and magnesium. 93.5% did not fulfill the WHO recommendations on physical activity. Only retinol (r=-0.602, p=0.039) and vitamin K1 (r=-0.693, p=0.012) in women were related to the severity of illness.Conclusions: Outpatients with schizophrenia do not follow WHO recommendations on healthy diets, neither physical activity. Both clinical severity of the illness and marital status and cohabitation were associated with poor eating habits and nutrients deficit. These data should be taken into account by the nursing staff when implementing specific care in routine clinical practice. (AU)
Subject(s)
Adult , Schizophrenia , Feeding Behavior , Cardiovascular DiseasesABSTRACT
Introduction:Negative symptoms can be grouped into five domains: apathy/avolition, anhedonia, asociality, alogia, and affective flattening. There are few validate self-rated measures that assess these five dimensions. Therefore, this study aimed to validate the Self-Evaluation of Negative Symptoms (SNS) in Spanish patients with schizophrenia.Material and methods:Cross-sectional, validation study in 104 outpatients with schizophrenia evaluated using the Spanish version of the following scales: Clinical Assessment Interview for Negative Symptoms (CAINS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale for Schizophrenia (CGI-SCH), Personal and Social Performance (PSP), Motivation and Pleasure Scale Self-Report (MAP-SR), 36-item Short-Form Health Survey (SF-36) and the Self-Evaluation of Negative Symptoms (SNS).Results Reliability:Internal consistency (Cronbach's alpha) was 0.915. Convergent validity: The Pearson correlation coefficient between MAP-SR and SNS Total scores was 0.660 (p<0.001). For PANSS-N, the correlation was 0.437 (p<0.005) and with the CAINS-Total was 0.478 (p<0.005). Divergent validity: The Pearson correlation coefficient between SNS and PSP was r=−0.372 (p≤0.001), and with SF-36 Physical and Mental Summary Component scores were r=−0.213 (p=0.066) and r=−0.144 (p=0.219), respectively. Discriminant validity: SNS Total scores were significantly statistically different according to the severity of the negative symptomatology rated by the CGI-SCH negative scale (p<0.001). (AU)
Introducción:Los síntomas negativos pueden agruparse en 5 dominios: apatía/abulia, anhedonia, conductas asociales, afasia y aplanamiento afectivo. Existen pocas medidas validadas autocalificadas que evalúen estas 5 dimensiones. Por tanto, el objetivo de este estudio fue validar la herramienta Self-Evaluation of Negative Symptoms (SNS, Autoevaluación de síntomas negativos) en pacientes españoles esquizofrénicos.Material y métodos:Estudio transversal de validación en 104 pacientes esquizofrénicos externos, evaluados utilizando la versión española de las escalas siguientes: Clinical Assessment Interview for Negative Symptoms (CAINS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale for Schizophrenia (CGI-SCH), Personal and Social Performance (PSP), Motivation and Pleasure Scale-Self-Report (MAP-SR), 36-item Short-Form Health Survey (SF-36) y la SNS.Resultados: Respecto a la fiabilidad,la consistencia interna (α de Cronbach) fue de 0,915. En cuanto a validez convergente, el coeficiente de correlación de Pearson entre las puntuaciones totales de MAP-SR y SNS fue de 0,660 (p < 0,001). Para PANSS-N, la correlación fue de 0,437 (p < 0,005) y de 0,478 (p < 0,005) con CAINS-Total. Respecto a la validez divergente, el coeficiente de correlación de Pearson entre las puntuaciones SNS y PSP fue de r = 0,372 (p ≤ 0,001) y con las puntuaciones de SF-36 Physical and Mental Summary Component fueron de r = −0,213 (p = 0,066) y r = −0,144 (p = 0,219), respectivamente. En la validez discriminante, las puntuaciones totales de SNS fueron diferentes desde un punto de vista estadístico significativo, conforme a la gravedad de la sintomatología negativa calificada por la escala negativa CGI-SCH (p < 0,001). (AU)
Subject(s)
Humans , Schizophrenia , Psychic Symptoms , Aphasia , ApathyABSTRACT
Introduction: Apathy is a negative symptom of schizophrenia and is associated with poor real world functioning. Therefore, it is important to have validated psychometric instruments to assess this symptom. This is the first study to validate the Spanish adaptation of the self-rated version of the Apathy Assessment Scale (AES-S) in patients with schizophrenia.Materials and methods: Naturalistic, cross-sectional, validation study in 104 patients with schizophrenia evaluated using the following scales: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS), and Apathy Evaluation Scale-self-rated version (AES-S).Results: Reliability: Internal consistency (Cronbach's alpha) was 0.908. Convergent validity: The Pearson correlation coefficient between AES-S and CAINS-MAP total scores was −0.483 (p<0.001). For SNS, total and avolition subscale scores were −0.803 and −0.639 (p<0.001), respectively. With the MAP-SR, the correlation coefficient was −0.727 (p<0.001). Divergent validity: The Pearson correlation coefficient between AES-S and PSP total scores was 0.504 (p<0.001). Furthermore, with the CDSS, the correlation coefficient was −0.431 (p<0.001). Discriminant validity: The AES-S discriminated between different levels of illness severity according to CGI-S scores. Factor analysis: A three-component solution explained 57.32% of the variance. Pearson correlations between coefficients were 12=0.265, 13=0.464, and 23=0.060. (AU)
Introducción: La apatía es un síntoma negativo de la esquizofrenia, y está asociada a un mal funcionamiento del mundo real. Por tanto, es importante disponer de instrumentos psicométricos validados para valorar este síntoma. Este es el primer estudio que valida la adaptación al español de la versión auto-evaluada de la escala de evaluación de la apatía (AES-S) en pacientes esquizofrénicos.Material y métodos: Estudio naturalista, transversal y de validación realizado en 104 pacientes esquizofrénicos evaluados utilizando las escalas siguientes: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS) y Apathy Evaluation Scale-self-rated version (AES-S).Resultados: Fiabilidad: La consistencia interna (alfa de Cronbach) fue de 0,908. Validez convergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y CAINS-MAP fue de −0,483 (p<0,001). Para SNS, las puntaciones totales y de la subescala de abulia fueron de −0,803 y −0,639 (p<0,001), respectivamente. En cuanto a la escala MAP-SR, el coeficiente de correlación fue de −0,727 (p<0,001). Validez divergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y PSP fue de 0,504 (p<0,001). Además, en la escala CDSS, el coeficiente de correlación fue de −0,431 (p<0,001). Validez discriminante: La escala AES-S discriminó entre los diferentes niveles de gravedad de la enfermedad, conforme a las puntuaciones CGI-S. Análisis factorial: Una solución de tres componentes explicó el 57,32% de la varianza. Las correlaciones de Pearson entre los coeficientes fueron de 1-2=0,265, 1-3=0,464 y 2-3=0,060. (AU)
Subject(s)
Humans , Schizophrenia , ApathyABSTRACT
INTRODUCTION: There are few published empirical data on the effects of COVID-19 on mental health, and until now, there is no large international study. MATERIAL AND METHODS: During the COVID-19 pandemic, an online questionnaire gathered data from 55,589 participants from 40 countries (64.85% females aged 35.80 ± 13.61; 34.05% males aged 34.90±13.29 and 1.10% other aged 31.64±13.15). Distress and probable depression were identified with the use of a previously developed cut-off and algorithm respectively. STATISTICAL ANALYSIS: Descriptive statistics were calculated. Chi-square tests, multiple forward stepwise linear regression analyses and Factorial Analysis of Variance (ANOVA) tested relations among variables. RESULTS: Probable depression was detected in 17.80% and distress in 16.71%. A significant percentage reported a deterioration in mental state, family dynamics and everyday lifestyle. Persons with a history of mental disorders had higher rates of current depression (31.82% vs. 13.07%). At least half of participants were accepting (at least to a moderate degree) a non-bizarre conspiracy. The highest Relative Risk (RR) to develop depression was associated with history of Bipolar disorder and self-harm/attempts (RR = 5.88). Suicidality was not increased in persons without a history of any mental disorder. Based on these results a model was developed. CONCLUSIONS: The final model revealed multiple vulnerabilities and an interplay leading from simple anxiety to probable depression and suicidality through distress. This could be of practical utility since many of these factors are modifiable. Future research and interventions should specifically focus on them.
Subject(s)
Anxiety/epidemiology , COVID-19/complications , COVID-19/psychology , Depression/epidemiology , Mental Health , Adult , Anxiety/etiology , COVID-19/epidemiology , Depression/etiology , Female , Global Burden of Disease , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2 , Stress, Psychological/etiology , Suicidal IdeationABSTRACT
INTRODUCTION: Coronavirus disease 2019 (COVID-19) forced Spain to implement unprecedented lockdown restriction. In this context, different factors could worsen sleep quality, but the impact of the pandemic and lockdown on sleep is still mostly unknown. In this cross-sectional study, we describe self-reported sleep disturbances in people without mental health disorders from a large Spanish sample (n = 15,070). METHODS: During the early phase of the lockdown (19-26 March), an online survey was launched using a snowball sampling method and included sociodemographic and clinical data along with the Depression, Anxiety, and Stress Scale (DASS-21) and the Impact of Event Scale (IES). Two items of the IES were employed to assess sleep characteristics. Descriptive and bivariate analysis and logistic regression models were performed. RESULTS: Difficulty initiating or maintaining sleep were reported by 23.9% of the sample and was associated in the regression model with age (OR = 1.008, p = .003), female sex (OR = 1.344, p < .001), an income reduction >50% (OR = 1.248, p = .037), having one (OR = 1.208, p = .029) and two or more (OR = 1.299, p = .035) elderly dependents, drinking alcohol (OR = 1.129, p = .024), and a higher score on DASS-21 depression (OR = 1.148, p < .001), anxiety (OR = 1.218, p < .001), or stress (OR = 1.302, p < .001) subscales, whereas being able to enjoy free time (OR = 0.604, p < .001) and painting or listening to music (OR = 0.853, p = .012) were protective factors. Dreams related to COVID-19 were reported by 12.9% of the sample and were associated in the regression model with female sex (OR = 1.617, p < .001), being married (OR = 1.190, p = .015), self-employed (OR = 1.373, p = .032), or a civil servant (OR = 1.412, p = .010), having been tested for COVID-19 (OR = 1.583, p = .012), having infected family or friends (OR = 1.233, p = .001), reading news about coronavirus (OR = 1.139, p = .023), drinking alcohol (OR = 1.251, p < .001), and higher scores on DASS-21 depression (OR = 1.102, p < .001), anxiety (OR = 1.222, p < .001), or stress (OR = 1.213, p < .001) subscales, while protective factors were older age (OR = 0.983, p < .001) and being retired (OR = 0.625, p = .045). CONCLUSIONS: These findings could help clinicians and public health systems design and deliver tailored interventions, such as internet-delivered campaigns, to promote sleep quality in the general population.
Subject(s)
COVID-19 , Aged , Anxiety/epidemiology , COVID-19/epidemiology , Communicable Disease Control , Cross-Sectional Studies , Depression/epidemiology , Female , Humans , Mental Health , Pandemics , Sleep , Stress, Psychological/epidemiologyABSTRACT
High prevalence of smoking in people with severe mental disorders (SMD) contributes to their medical morbidity and reduced life expectancy. Despite the evidence of gender differences in smoking cessation, few studies have tested those differences among people with SMD. This is a non-randomized, open-label, prospective, 9-month follow-up multicentre trial to examine gender differences in the efficacy, safety and tolerability of a Multi-Component Smoking Cessation Support Programme (McSCSP). The results showed that there were no significant differences in short- (males 44.9% vs females 57.7%, chi-square = 1.112, p = 0.292) or long-term efficacy (week 24: males 40.8%, females 42.3%, chi-square = 0.016, p = 0.901; week 36: males 36.7%, females 38.5%, chi-square = 0.022, p = 0.883) between gender, neither controlled by diagnosis or treatment. Regarding safety and tolerability, there was significant increase in abdominal perimeter in males [from 105.98 (SD 13.28) to 108.52 (SD 14.01), t = -3.436, p = 0.002)], but not in females. However, there were no significant gender differences in adverse events (constipation, abnormal/vivid dreams, nausea/vomiting or skin rash/redness around patch site). In conclusion, we have demonstrated that is effective and safe to help either male or female patients with stabilized SMD to quit smoking. However, it might be a tendency in females to respond better to varenicline treatment in the short-term. Future research with larger samples is required to more clearly determine whether or not the there are differences, in addition to their reliability and robustness.
La elevada prevalencia del tabaquismo en personas con trastorno mental grave (TMG) contribuye a su morbilidad médica y reduce su esperanza de vida. A pesar de la existencia de diferencias de género en el cese del tabaquismo, pocos estudios han evaluado esas diferencias en personas con TMG. Este es un ensayo multicéntrico de seguimiento prospectivo, no aleatorizado, abierto de 9 meses para examinar las diferencias de género en la eficacia, seguridad y tolerabilidad de un programa multicomponente de apoyo para el cese del tabaquismo (McSCSP). Los resultados mostraron que no hubo diferencias de género significativas en la eficacia a corto (hombres 44,9% vs mujeres 57,7%, chi cuadrado = 1,112, p = ,292) ni a largo plazo (semana 24: hombres 40,8%, mujeres 42,0.3%, chi cuadrado = 0.016, p = ,901; semana 36: hombres 36,7%, mujeres 38,5%, chi cuadrado = 0,022, p = ,883), incluso controlando por diagnóstico o tratamiento. Con respecto a la seguridad y la tolerabilidad, hubo un aumento significativo en el perímetro abdominal en los hombres [de 105,98 (DT 13,28) a 108,52 (DT 14,01), t = -3,436, p = ,002)], pero no en las mujeres. Sin embargo, no hubo diferencias de género significativas en los eventos adversos (estreñimiento, sueños anormales/vívidos, náuseas/vómitos o erupción cutánea/enrojecimiento alrededor de la zona del parche). En conclusión, hemos demostrado que es efectivo y seguro ayudar a los hombres y mujeres con TMG estabilizados a dejar de fumar. Sin embargo, podría haber una tendencia en las mujeres a responder mejor al tratamiento con vareniclina a corto plazo. Se requiere investigación futura con muestras más amplias para determinar con más claridad la existencia de diferencias, además de la fiabilidad y robustez.
Subject(s)
Smoking Cessation , Substance Withdrawal Syndrome , Female , Humans , Male , Nicotine , Nicotinic Agonists/adverse effects , Prospective Studies , Reproducibility of Results , Sex Factors , Smoking Cessation/methodsABSTRACT
La elevada prevalencia del tabaquismo en personas con trastorno mentalgrave (TMG) contribuye a su morbilidad médica y reduce su esperanzade vida. A pesar de la existencia de diferencias de género en el cese deltabaquismo, pocos estudios han evaluado esas diferencias en personascon TMG. Este es un ensayo multicéntrico de seguimiento prospectivo,no aleatorizado, abierto de 9 meses para examinar las diferencias de género en la eficacia, seguridad y tolerabilidad de un programa multicomponente de apoyo para el cese del tabaquismo (McSCSP). Los resultadosmostraron que no hubo diferencias de género significativas en la eficaciaa corto (hombres 44,9% vs mujeres 57,7%, chi cuadrado = 1,112, p =,292) ni a largo plazo (semana 24: hombres 40,8%, mujeres 42,0.3%, chicuadrado = 0.016, p = ,901; semana 36: hombres 36,7%, mujeres 38,5%, chi cuadrado = 0,022, p = ,883), incluso controlando por diagnóstico otratamiento. Con respecto a la seguridad y la tolerabilidad, hubo unaumento significativo en el perímetro abdominal en los hombres [de105,98 (DT 13,28) a 108,52 (DT 14,01), t = -3,436, p = ,002)], pero no enlas mujeres. Sin embargo, no hubo diferencias de género significativasen los eventos adversos (estreñimiento, sueños anormales/vívidos, náuseas/vómitos o erupción cutánea/enrojecimiento alrededor de la zonadel parche). En conclusión, hemos demostrado que es efectivo y seguroayudar a los hombres y mujeres con TMG estabilizados a dejar de fumar.Sin embargo, podría haber una tendencia en las mujeres a respondermejor al tratamiento con vareniclina a corto plazo. Se requiere investigación futura con muestras más amplias para determinar con más claridadla existencia de diferencias, además de la fiabilidad y robustez. (AU)
High prevalence of smoking in people with severe mental disorders(SMD) contributes to their medical morbidity and reduced lifeexpectancy. Despite the evidence of gender differences in smokingcessation, few studies have tested those differences among peoplewith SMD. This is a non-randomized, open-label, prospective,9-month follow-up multicentre trial to examine gender differencesin the efficacy, safety and tolerability of a Multi-Component SmokingCessation Support Programme (McSCSP). The results showed thatthere were no significant differences in short- (males 44.9% vs females57.7%, chi-square = 1.112, p = 0.292) or long-term efficacy (week 24:males 40.8%, females 42.3%, chi-square = 0.016, p = 0.901; week 36:males 36.7%, females 38.5%, chi-square = 0.022, p = 0.883) between gender, neither controlled by diagnosis or treatment. Regarding safetyand tolerability, there was significant increase in abdominal perimeterin males [from 105.98 (SD 13.28) to 108.52 (SD 14.01), t = -3.436,p = 0.002)], but not in females. However, there were no significantgender differences in adverse events (constipation, abnormal/vividdreams, nausea/vomiting or skin rash/redness around patch site). Inconclusion, we have demonstrated that is effective and safe to helpeither male or female patients with stabilized SMD to quit smoking.However, it might be a tendency in females to respond better tovarenicline treatment in the short-term. Future research with largersamples is required to more clearly determine whether or not thethere are differences, in addition to their reliability and robustness. (AU)